|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
230,290,000 |
Market
Cap: |
138.17(K) |
Last
Volume: |
11,847,187 |
Avg
Vol: |
11,814,994 |
52
Week Range: |
$0.0001 - $0.055 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Endo International is a holding company. Through its subsidiaries, Co. is engaged in specialty pharmaceuticals. Co.'s segments are: Branded Pharmaceuticals, which includes branded products to treat and manage conditions in the areas of urology, orthopedics, endocrinology and bariatrics, among others; Sterile Injectables, which consists of branded sterile injectable products; Generic Pharmaceuticals, which includes generic product families that treat and manage a range of medical conditions; and International Pharmaceuticals, which includes products serving therapeutic areas, including attention deficit hyperactivity disorder, pain, women's health, oncology and transplantation.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kelso Partners V L P |
10% Owner |
|
2005-10-13 |
4 |
OE |
$2.42 |
$130,746 |
I/I |
49,931 |
17,246,015 |
|
- |
|
Kelso Equity Partners V L P |
10% Owner |
|
2005-10-13 |
4 |
OE |
$2.42 |
$141,749 |
I/I |
54,133 |
18,697,157 |
|
- |
|
Endo Pharma Llc |
10% Owner |
|
2005-10-13 |
4 |
OE |
$2.42 |
$169,527 |
D/D |
64,741 |
22,361,051 |
|
- |
|
Kelso Investment Assoc V L P |
10% Owner |
|
2005-10-13 |
4 |
OE |
$2.42 |
$141,749 |
I/I |
54,133 |
18,697,157 |
|
- |
|
Manogue Caroline B |
Exec. V.P., CLO & Secy |
|
2005-10-12 |
4 |
S |
$26.04 |
$2,789,118 |
D/D |
(107,109) |
72,801 |
|
- |
|
Manogue Caroline B |
Exec. V.P., CLO & Secy |
|
2005-10-12 |
4 |
OE |
$2.42 |
$525,426 |
D/D |
179,910 |
179,910 |
|
- |
|
Lankau Peter A |
President & CEO |
|
2005-10-12 |
4 |
S |
$26.04 |
$2,169,575 |
D/D |
(83,317) |
56,795 |
|
- |
|
Lankau Peter A |
President & CEO |
|
2005-10-12 |
4 |
OE |
$2.42 |
$404,924 |
D/D |
140,112 |
140,112 |
|
- |
|
Black Jeffrey R |
Exec. V.P., CFO and Treasurer |
|
2005-10-12 |
4 |
S |
$26.04 |
$40,660,314 |
D/D |
(1,561,456) |
1,027,868 |
|
- |
|
Black Jeffrey R |
Exec. V.P., CFO and Treasurer |
|
2005-10-12 |
4 |
OE |
$2.42 |
$7,203,489 |
D/D |
2,589,324 |
2,589,324 |
|
- |
|
Lee David A H |
Exec. V.P and CSO |
|
2005-10-12 |
4 |
S |
$26.04 |
$46,286,412 |
D/D |
(1,777,512) |
1,174,537 |
|
- |
|
Lee David A H |
Exec. V.P and CSO |
|
2005-10-12 |
4 |
OE |
$2.42 |
$8,267,668 |
D/D |
2,952,049 |
2,952,049 |
|
- |
|
Ammon Carol A |
Director |
|
2005-10-12 |
4 |
S |
$26.04 |
$116,467,363 |
D/D |
(4,472,633) |
2,861,233 |
|
- |
|
Ammon Carol A |
Director |
|
2005-10-12 |
4 |
OE |
$2.42 |
$19,557,996 |
D/D |
7,333,866 |
7,333,866 |
|
- |
|
Hyatt Michael |
Director |
|
2005-10-12 |
4 |
S |
$26.04 |
$2,334,798 |
I/I |
(89,662) |
50,000 |
|
- |
|
Hyatt Michael |
Director |
|
2005-10-12 |
4 |
S |
$26.04 |
$4,328,291 |
D/D |
(166,217) |
400,000 |
|
- |
|
Connors James J Ii |
10% Owner |
|
2005-10-12 |
4 |
OE |
$2.42 |
$40,846,462 |
I/I |
15,036,789 |
17,295,946 |
|
- |
|
Connors James J Ii |
10% Owner |
|
2005-10-12 |
4 |
S |
$26.04 |
$427,011,628 |
I/I |
(16,398,296) |
32,332,736 |
|
- |
|
Connors James J Ii |
10% Owner |
|
2005-10-12 |
4 |
OE |
$2.42 |
$44,283,434 |
I/I |
16,302,040 |
18,751,290 |
|
- |
|
Connors James J Ii |
10% Owner |
|
2005-10-12 |
4 |
S |
$26.04 |
$462,941,906 |
I/I |
(17,778,107) |
35,053,329 |
|
- |
|
Kelso Partners V L P |
10% Owner |
|
2005-10-12 |
4 |
OE |
$2.42 |
$40,846,462 |
I/I |
15,036,789 |
17,295,946 |
|
- |
|
Kelso Partners V L P |
10% Owner |
|
2005-10-12 |
4 |
S |
$26.04 |
$427,011,628 |
I/I |
(16,398,296) |
32,332,736 |
|
- |
|
Endo Pharma Llc |
10% Owner |
|
2005-10-12 |
4 |
OE |
$2.42 |
$52,961,214 |
D/D |
19,496,587 |
22,425,792 |
|
- |
|
Endo Pharma Llc |
10% Owner |
|
2005-10-12 |
4 |
S |
$26.04 |
$553,660,006 |
D/D |
(21,261,905) |
41,922,379 |
|
- |
|
Kelso Equity Partners V L P |
10% Owner |
|
2005-10-12 |
4 |
OE |
$2.42 |
$44,283,434 |
I/I |
16,302,040 |
18,751,290 |
|
- |
|
825 Records found
|
|
Page 27 of 33 |
|
|